OvaRenew
disruptive fertility solution
impaired egg quality treatment Potenza Medica
Global fertility services market
global commercialisation
commercialisation of innovative fertility products
women
line therapy
focus
child
global markets
innovative combining of new findings
disruptive findings of stem cells
developed world
country health
initial market
business opportunity
significant health complications
Comprehensive business plan
practical strategy available
nutritive science
GMP
ethics
procedures
ovaries
development
alignement
close dialogue
regulators
cell procurement
decreasing cost
invasiveness
risk assesment
IP protection
regulatory requirements
regulated industries
clinical trials
ovarian infertility
deepest human needs-reproduction
mio
investment
final product
oocytes
safety
current industry practice
expenditures
feasibility study
novelty
defined conditions
worldwide expansion
Suitable contract manufacturer
woman
years
Phase2
growth rates
EU
hand
substances